Earlier Use of Mycophenolate Mofetil in Scleroderma: Clinical Trial

Oct 24, 2024

Lung disease is the leading cause of death in scleroderma, affecting over 50% of individuals with the disease. Currently, treatments to calm the immune system are only given when lung disease is progressive or severe. We want to determine if earlier intervention is effective in preserving lung function.

Read More

Discovering New Blood Tests for Patients with Autoimmune Inflammatory Muscle Diseases

Aug 15, 2024

Autoimmune Inflammatory Myopathies (AIMs) are under-recognized and disproportionally affect racial/ethnic minorities. This research will help improve the future quality of life for patients with AIMs by improving diagnosis and treatment.

Read More

Developing classification criteria to identify kidney failure in people with scleroderma

Jun 20, 2024

A serious complication of scleroderma is scleroderma renal crisis (sudden kidney failure). Currently, there is no standardized set of criteria to define this complication which leads to poor understanding of the problem and a lack of more effective treatments. This study aims to create a new classification criteria to improve outcomes for people living with this disease.

Read More

Understanding the experiences of patients with antiphospholipid antibodies

Sep 13, 2023

Almost half of lupus patients are at risk for blood clots. Previous studies have shown that patients do not have the resources they need to understand this diagnosis, make decisions about it, or discuss it with doctors. This study aims to create learning resources and tools to improve communication between doctors and patients.

Read More

Multisystem Inflammatory Syndrome in Children: Predicting severity and treatments for better outcomes

Apr 10, 2023

Multisystem Inflammatory Syndrome in Children (MIS-C) can occur weeks after a mild or even asymptomatic infection of COVID-19. In this study, we will use machine learning and artificial intelligence to rapidly diagnose MIS-C and predict which child will develop severe disease.

Read More

Understanding Childhood Arthritis to Improve Treatment

Feb 02, 2022

Arthritis is a chronic, disabling disease of childhood. Many children will continue to have arthritis as adults. We will develop tests that enable us to learn about the biology of each child’s disease to ensure we use biologic therapies in the safest, most beneficial and cost-effective way to improve health and quality of life.

Read More

Towards Understanding the Use of Hydroxychloroquine in Patients with Systemic Lupus Erythematosus

Jan 18, 2022

The main side effect of long-term use of hydroxychloroquine is eye damage. At present, we cannot accurately predict which patients with systemic lupus erythematosus are most likely to have a flare of their symptoms once we lower the dose of this drug. It is also unclear what causes the risk of eye damage. Our study will fill these knowledge gaps…

Read More

Canadian Research Group of Rheumatology in Immuno-Oncology (CAN-RiO)

Feb 23, 2021

The Canadian Research Group of Rheumatology in Immuno-Oncology (CAN-RiO) is a network of 19 rheumatologists across Canada (see map) with expertise in the assessment and management of rheumatic complications of cancer immunotherapy. CanRIO’s mission is to improve the care of cancer patients across Canada receiving immunotherapy, who develop rheumatic complications or who have pre-existing autoimmune conditions.

Read More

Building Knowledge to Improve Primary Health Care for Indigenous Peoples

Aug 13, 2020

The Indigenous Primary Health Care and Policy Research (IPHCPR) Network will support knowledge building to improve delivery of primary health care to Indigenous peoples. It will bring together researchers, health system partners and Indigenous community members to help define the developing knowledge area of Indigenous primary health care...

Read More

Original Biologics and Biosimilars – are they equally effective and safe?

Aug 06, 2020

Biologic medications or ‘Biologics’, also known as anti-TNF agents, have provided major advances to the treatment of Rheumatoid Arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), due to their unparalleled efficacy. Ten thousand British Columbians use biologics for RA, PsA and AS...

Read More

Is Internet Delivered Cognitive Behavioral Therapy feasible for insomnia in lupus patients?

Jul 27, 2020

Sleep disturbances, including difficulty falling asleep, staying asleep, and/or waking up early in the morning are all symptoms of insomnia. They are, reported in up to 80% of persons with Systemic Lupus Erythematosus (SLE). Sleep disturbances worsen other symptoms of SLE including fatigue, pain, and depression causing poor quality of life.

Read More

The impact of antimalarial drugs in arthritis patients exposed to COVID-19

Jul 23, 2020

The current pandemic offers a chance to improve our understanding of how infections such as COVID-19 affect patients with autoimmune inflammatory diseases. We can assess the impact of the medication used to treat their disease on infection and how infections affect their psychological health.

Read More

Blood proteins linked to lupus will lead to better diagnosing and understanding of the disease

Jun 04, 2019

Lupus or systemic lupus erythematosus (SLE) is a complex and unpredictable disease that can lead to irreversible organ damage. SLE patients have specific proteins in their blood that healthy people do not. This study will determine which of the 10 proteins identified in a group of SLE patients are linked to SLE. This information could represent a new signal for…

Read More

Preventing Complications in an Indigenous Community: Improving Quality of Care

Feb 07, 2019

Indigenous communities have higher occurrences of chronic diseases (including inflammatory diseases) and more difficulty accessing health care services than other populations in Canada. This sub-project of the PRECISION study will evaluate if the use of a nurse case manager in a First Nations community can result in care that is appropriate, respectful, and culturally relevant for those with chronic diseases.

Read More

Reducing the Burden of Complications from Inflammatory Diseases

Feb 07, 2019

Due to improved treatments, people with inflammatory diseases of the skin, joint, or bowel are more likely to die from medical complications of the disease than the disease itself. This sub-project of the PRECISION study will examine how common the complications are, and what factors (such as inflammation) increase or decrease the risk of these complications.

Read More

Risk of Retinal Toxicity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Long-term Hydroxychloroquine Therapy

Feb 06, 2019

The drug hydroxychloroquine (HCQ) is commonly used to treat systemic lupus erythematosus and rheumatoid arthritis, as it reduces the severity of the disease, lessens medical complications, all which contribute to a longer life. However, a serious long-term side-effect is eye damage that may cause vision loss.

Read More

The MyLupusGuide: An empowering eHealth tool to support self-management of lupus

Dec 20, 2017

MyLupusGuide has been developed to provide reliable and easily accessible information, support, and other tools to help people manage their lupus. This study will investigate the use of MyLupusGuide and its effectiveness in improving self-management and better health for those with the disease.

Read More

Improving quality of arthritis care for Indigenous populations

Jul 04, 2017

Arthritis, particularly inflammatory arthritis, is the most common chronic disease in Indigenous populations. This research aims to find solutions to the inequalities in inflammatory arthritis care and outcomes in Canada’s Indigenous populations. Preferences for care and treatment will be determined, and tools will be developed to assist them and their health care providers to agree on treatment choices and expectations.

Read More